Trial Profile

A single dose clinical pharmacokinetic study assessing AV 104 in subjects with mild to moderate chronic liver disease

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nalmefene (Primary)
Indications Prurigo nodularis; Pruritus
Focus Pharmacokinetics
Sponsors Avior Bio

Most Recent Events

15 Sep 2023 According to a Hillstream Biopharma, company intends to complete this study over approximately the next 12 months after alignment with the US FDA.
17 Mar 2021 New trial record
08 Mar 2021 According to an Avior Bio media release, the company plans to complete this and another pharmacokinetic study in normal volunteers. Completion of these studies will unable to finalize the design of phase II program in the treatment of chronic liver disease associated pruritus.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com